View all WisdomTree insights in the BioRevolution category.
From obesity therapies to AI-powered diagnostics, the BioRevolution is moving from promise to progress. Christopher Gannatti analyzes the company-specific catalysts behind the WisdomTree BioRevolution Fund's (WDNA) recent acceleration and what they could mean for the theme going forward.
Read the article
A single dog’s cancer diagnosis shows how AI can turn biology into a data problem, reshaping what’s possible in medicine. Christopher Gannatti explains how this shift reframes AI investing—spanning everything from mega-cap tech to bio-revolution breakthroughs.
Read the article
AI is reshaping industries far beyond tech, and broad ETFs may miss the mark. Christopher Gannatti explains how WisdomTree’s six specialized Funds segment AI exposure across cybersecurity, biotech, cloud and more, helping investors to truly align with the component of the AI economy for which they are seeking exposure.
Read the article
In developed international equities, with a tougher period for equities in 2025 value and high dividends have delivered relative outperformance. Christopher Gannatti unpacks why the early 2025 outperformance of the WisdomTree International High Dividend Fund signals a shift in investor sentiment and how sector tilts and yield dynamics set it apart from quality-focused strategies like the WisdomTree International Quality Dividend Growth Fund.
Read the article
After years of underwhelming performance, biotech may finally be ready for a breakthrough in 2025. Chris Gannatti highlights how advancements in gene editing, AI-driven drug discovery and policy support are laying the foundation for a sector-wide resurgence.
Read the article
Biotech breakthroughs, from GLP-1 drugs to regenerative medicine, are reshaping healthcare—and equity markets are starting to take notice. Chris Gannatti dives into the science and market trends driving a biotech resurgence.
Read the article
The biotechnology sector has faced stock performance challenges, but private markets may be signaling a more optimistic future for the industry. Christopher Gannatti discusses the rising significance of venture capital mega-rounds and explores the latest scientific advances, such as breakthroughs in CAR-T cell therapies for autoimmune conditions.
Read the article
At WisdomTree, we collaborate with Dr. Jamie Metzl on our BioRevolution strategy. Dr. Metzl recently published a book, Superconvergence: How the Genetics, Biotech, and AI Revolutions Will Transform Our Lives, Work, and World. In this installment of our BioRevolution blog series, Christopher Gannatti summarizes a few key points from the book, including breakthroughs in stem cell transplants for diabetes. 
Read the article
At WisdomTree, we collaborate with Dr. Jamie Metzl on our BioRevolution strategy. Dr. Metzl recently published a book, Superconvergence: How the Genetics, Biotech, and AI Revolutions Will Transform our Lives, Work, and World. In the fifth part of our BioRevolution blog series, Christopher Gannatti summarizes a few key points from the book including the potential of gene therapy. 
Read the article
The recent earnings reports from major technology companies have raised questions about the return on investment in AI. Christopher Gannatti explores the challenges and potential of biotechnology investments amidst a shifting economic landscape.
Read the article
At WisdomTree, we collaborate with Dr. Jamie Metzl on our BioRevolution strategy. Dr. Metzl recently published a book, Superconvergence: How the Genetics, Biotech, and AI Revolutions Will Transform our Lives, Work, and World. In the fourth part of our BioRevolution blog series, Chris Gannatti summarizes a few key points from the book including the potential of chimeric antigen receptor (CAR) T-cell therapy. 
Read the article
At WisdomTree, we work with Dr. Jamie Metzl on a strategy that we term the BioRevolution. Dr. Metzl recently a book, Superconvergence: How the Genetics, Biotech, and AI Revolutions Will Transform our Lives, Work, and World. In the third part of our BioRevolution blog series, Christopher Gannatti summarizes a few key points from the book including the evolution of AlphaFold 3. 
Read the article
